Bryan Johnson’s “Clone”: Where the Sci-Fi Ends and the Science Begins

Key Points:

• Bryan Johnson created induced pluripotent stem cells (iPSCs) with his genome that can become many cell types.
• Stem-cell-derived replacement cells are reaching patients, and personalized cells and organoids can be used to study disease and test drugs.
• Reversing aging by growing replacement organs, creating endless “young blood,” or injecting young cells is decades away.

Bryan Johnson has spent years trying to make his 48-year-old body act younger. Now, a recent post makes it sound like there could now be not just one Bryan Johnson but two.

“I just cloned myself…as a newborn,” the tech entrepreneur and longevity celebrity announced in July. His new “baby-Bryan,” Johnson explained, currently lives in a petri dish. He proposed using it as his blood donor, testing experimental therapies, generating rejuvenating cells, and growing replacement organs. “This technology gives us a path to reverse aging,” he wrote.

It sounds like Johnson has crossed from biohacking into science fiction. He hasn’t. Johnson did something considerably less cinematic—but scientifically far more compelling.

First: No, Bryan Johnson Did Not Clone Himself

As per Johnson’s description, researchers exposed his blood cells to Yamanaka factors, which reprogrammed mature adult cells into induced pluripotent stem cells (iPSCs). These cells, like embryonic stem cells, can become many cell types under certain conditions.

This iPSC reprogramming technology won the 2012 Nobel Prize in Physiology or Medicine and transformed regenerative medicine by allowing scientists to reset adult cells into stem cells that can become neurons, heart cells, retinal cells, blood cells, and other cell types. David Sinclair’s work with Life Biosciences uses a related idea—reprogramming cells toward a younger state, but stopping short of fully resetting their identity.

But creating iPSCs of himself is a far cry from creating another human being, a newborn, an embryo, or even a tiny version of himself. So Johnson hasn’t cloned Bryan Johnson. He’s created a bunch of cells with his genome that can be used to turn into all sorts of bits you may find in the real Bryan Johnson—which could eventually be surprisingly useful.

Could “Baby Bryan” Test Drugs for Adult Bryan?

This may be the most realistic part of Johnson’s vision. Scientists already use patient-derived iPSCs to create organoids—miniature tissue models for studying disease and testing drugs—and Johnson has proposed an “organoid avatar” for testing interventions.

But organoids are not miniature people: they cannot capture whole-body effects, and reprogramming cells into iPSCs actually erases many aging-related features researchers may want to study. “Baby Bryan” could become a useful personalized laboratory, but not a perfect stand-in for Bryan.

Injecting Himself With “Young” Cells?

Here Johnson’s idea moves from plausible research toward experimental medicine. Stem-cell-derived replacement cells are already reaching patients: in a 2025 Phase I/II Parkinson’s study, iPSC-derived dopamine-producing cells survived transplantation, produced dopamine and showed no tumors over two years, with some patients improving.

But replacing a specific cell type lost to disease is very different from injecting generic “young” cells to reverse aging. Residual undifferentiated iPSCs can proliferate uncontrollably and form tumors, requiring careful differentiation and purification. There is currently no established therapy showing that adding young iPSC-derived cells broadly rejuvenates the human body.

Can He Become His Own “Blood Boy”?

In principle, iPSCs could eventually provide personalized blood cells. In practice, producing the enormous quantities of safe, functional red blood cells required for routine transfusion remains a substantial manufacturing challenge. More importantly, there is no compelling evidence that continuously supplying yourself with genetically identical, lab-made “young blood” would rejuvenate your body.

The provocative phrase may echo Johnson’s earlier experiments with plasma from his teenage son, but iPSC-derived blood would represent a fundamentally different technology. The intriguing scientific opportunity is not creating an eternally youthful blood donor in a dish; it’s developing renewable, standardized sources of blood cells for medicine.

And Can He Grow Himself a New Kidney?

This is simultaneously the most spectacular and most speculative part of Johnson’s proposal. Scientists can already grow organoids resembling miniature kidneys, livers, intestines, brains and other organs. But these are not simply tiny versions of transplantable adult organs.

A human kidney contains complex architecture, multiple specialized cell populations, blood vessels, nerves, and plumbing capable of filtering roughly 180 liters of fluid per day, which is more than the amount of volume to fill up the tank of two Ford F150 pickup trucks. Building that entire system from scratch—and connecting it safely to a human body—is vastly harder than persuading stem cells to form kidney-like tissue in a dish. Even experimental kidney organoids remain immature, and safety is an issue.

Personalized, iPSC-derived replacement organs remain an extraordinary goal of regenerative medicine. They are not currently sitting on a laboratory shelf waiting for Johnson to need them.

Stranger (and More Interesting) Than Fiction

Strip away “baby Bryan” and the clone rhetoric, and Johnson’s project points toward a legitimate scientific revolution. A bank of personalized pluripotent cells could generate neurons, cardiac cells, retinal cells, or organoids for research, drug testing, and potentially transplantation. Some applications are already reaching clinical trials; others—including replacement organs, rejuvenating cell infusions, and youthful blood—remain far more speculative.

That distinction matters in longevity science, where biologically conceivable and clinically proven can be decades apart. Johnson hasn’t cloned himself, but he has created a renewable source of his own cells that could theoretically become many different tissues. That’s extraordinary enough without calling it a newborn.